Source: Benzinga

Gyre Therapeutics: Gyre Therapeutics Q4 EPS $0.00 Up From $(1.39...

Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!

Read full article »
Annual Revenue
$100-500M
Employees
500-1.0K
Charles Wu's photo - CEO of Gyre Therapeutics

CEO

Charles Wu

CEO Approval Rating

82/100

Read more